Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy

NCT00298038 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.

NCT NCT00298038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00298038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy
Lead sponsor
Bausch Health Americas, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 19, 2005
Completion date
August 15, 2008
Enrollment
299 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic encephalopathy